COVID-19 is caused by the novel Coronavirus, SARS-CoV-2, and has been spreading rapidly.
Although over 100 vaccines and numerous therapies are under development, their efficacy
Importantly, SARS-CoV-2 is evolving rapidly with genetic mutations that may further impede the efficacy of potential vaccines and therapies. A more virulent strain could also cause a second wave of infections, even in those patients who may have previously had the disease.
Mapping the genetic variations between the isolates/strains and predicting the immune responses of patients are vital to understanding strain-virulence, disease-spread, and resistance against vaccines and therapies.
20+ purpose-built and validated genomic algorithms are available to enable the sequencing and characterization of the SARS-CoV-2 isolates: assemble viral genomes, detect novel mutations and assess phylogenetic differences.
The ability of COVID-19 patients to develop antibodies and natural immunity against the virus is limited in those with severe/fatal disease. Our B-Cell/T-Cell receptor repertoire sequencing analysis allows scientists to screen patients pre/post-vaccination or during therapy to uncover COVID-19 immunity or disease progression
Our Svastia platform has offered screening and validation of drug targets in oncology for pharmaceutical customers for over three years. We have utilized our in-house expertise and resources to identify and analyze drug targets for COVID-19. We are proud to be making the preliminary report freely available upon request.
Indian Institute of Technology (Madras)